Pagenax 120 mg/ml Injection 1's

Pagenax 120 mg/ml Injection 1's is used to treat eye conditions that may affect your vision, such as neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). AMD is a condition that leads to vision loss due to the formation of abnormal blood vessels in the retina. DME is a complication of diabetes that causes swelling in the macula, the part of the retina responsible for sharp, central vision.

Pagenax 120 mg/ml Injection 1's contains brolucizumab, which is a monoclonal antibody. It blocks VEGF (vascular endothelial growth factor), a protein involved in the formation of abnormal blood vessels in the retina. This helps reduce fluid leakage, prevent further vision loss, and improve vision in patients with these eye conditions. 

A healthcare professional will administer Pagenax 120 mg/ml Injection 1's. This medicine may sometimes cause side effects, such as eye discomfort, redness, or increased intraocular pressure. Most of these side effects do not require medical treatment and will subside with time. However, if they persist or worsen, see a doctor.

Pagenax 120 mg/ml Injection 1's should not be received if you are allergic to it. Let your doctor know if you have ever had any eye diseases such as glaucoma, dark floating spots, retinal vascular occlusion, retinal vasculitis, or any previous eye treatments before receiving Pagenax 120 mg/ml Injection 1's. If you are pregnant or breastfeeding, please consult a doctor before taking Injection. Pagenax 120 mg/ml Injection 1's is not recommended for children, as its safety and efficacy have not been established.

Pagenax 120 mg/ml Injection 1's is used to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The detailed uses of Pagenax 120 mg/ml Injection 1's are as follows:

• Wet Age-Related Macular Degeneration (AMD) Treatment: Pagenax 120 mg/ml Injection 1's treats wet AMD by blocking VEGF-A, reducing abnormal blood vessel growth and leakage, slowing disease progression, and preserving vision.
• Diabetic Macular Edema (DME) Treatment: Pagenax 120 mg/ml Injection 1's treats diabetic macular edema (DME) by blocking VEGF-A, reducing fluid leakage and swelling in the retina, and improving vision.

• Follow your doctor’s instructions on the dosage and timing of this medication to ensure safe and effective use.
• Pagenax 120 mg/ml Injection 1's should be administered by a nurse or doctor to ensure proper dosage, technique, and monitoring for any potential side effects or complications.
• Do not self-administer.

Pagenax 120 mg/ml Injection 1's provides significant benefits for patients with wet AMD and DME because it reduces abnormal blood vessel formation and fluid leakage. This helps to prevent vision loss and improve vision. The drug is supplied directly into the eye via pre-filled injection, usually on a predetermined schedule that changes based on the patient's response. Pagenax 120 mg/ml Injection 1's blocks VEGF (vascular endothelial growth factor), a protein involved in the formation of abnormal blood vessels in the retina. This helps reduce fluid leakage, prevent further vision loss, and improve vision in patients with these eye conditions.

Let the doctor know if you are allergic to the Pagenax 120 mg/ml Injection 1's. Before starting treatment with Pagenax 120 mg/ml Injection 1's, inform your doctor about any other medications or herbal products you are taking. If you are pregnant or nursing, speak with your doctor. Pagenax 120 mg/ml Injection 1's is not recommended for use in conditions like ocular/periocular infections and active intraocular infections. Tell your doctor if you have a history of eye disorders such as glaucoma, dark floating spots, retinal vascular occlusion, retinal vasculitis, or any past eye treatments. Pagenax 120 mg/ml Injection 1's is not recommended for children under 18 years old.